查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086087

多發性骨髓瘤治療市場：2026-2032年全球市場預測（按藥物類別、治療階段、治療方案、給藥途徑、患者年齡、治療階段、患者類型和最終用戶分類）

Multiple Myeloma Drug Market by Drug Class, Line Of Therapy, Treatment Regimen, Route Of Administration, Patient Age, Line of Treatment, Patient Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多發性骨髓瘤治療市場規模將成長至 134.6 億美元，複合年成長率為 7.29%。

主要市場統計數據
基準年 2025 82.2億美元
預計年份：2026年 88億美元
預測年份 2032 134.6億美元
複合年成長率 (%) 7.29%

多發性骨髓瘤治療市場簡介

多發性骨髓瘤是一種漿細胞來源的惡性腫瘤，仍然是血液腫瘤學領域最棘手的疾病之一。此病以反覆復發、克隆進展、骨髓浸潤、免疫抑制、腎臟併發症、貧血和骨骼病變為特徵，因此，無論患者是新診斷、復發或難治性，都需要有效的治療方法。

多發性骨髓瘤治療領域的變革性變化

多發性骨髓瘤的治療模式正在經歷結構性轉變，從傳統的化療中心的療法轉向多機制、免疫療法和基於生物標記的治療策略。抗CD38抗體是許多第一線和復發治療方案的基礎。同時，針對BCMA的CAR-T療法和雙特異性抗體正在重新定義多重抗藥性、復發或難治性多發性骨髓瘤的治療前景。

人工智慧對多發性骨髓瘤治療的累積影響

人工智慧（AI）正逐漸成為多發性骨髓瘤藥物發現、開發、診斷和治療最佳化的基礎層。在研發領域，AI驅動的標靶發現、蛋白質建模、篩檢優先排序和轉化分析正助力識別新的抗原、抗藥性路徑和合理的聯合治療策略。這些工具在多發性骨髓瘤這種以基因組多樣性和治療性克隆演化為特徵的疾病中發揮著尤為重要的作用。

多發性骨髓瘤治療市場的關鍵區域洞察

北美地區在多發性骨髓瘤治療創新方面仍處於主導地位，這得益於其高額的腫瘤治療支出、FDA批准療法的快速推廣、完善的臨床試驗基礎設施以及強大的專家網路。美國透過廣泛應用抗CD38抗體、CAR-T療法、雙特異性抗體以及循證指南來滿足區域需求，而加拿大則專注於衛生技術評估（HTA）和公共資助的准入途徑。在全部區域，治療標準受到監管審查、指南更新、移植合格評估、專科藥房分銷以及真實世界安全性監測的顯著影響。

集團對多發性骨髓瘤療法商業策略的關鍵見解

包括美國、加拿大、日本、德國、法國、義大利和英國在內的七國集團（G7）在多發性骨髓瘤治療市場仍佔據核心地位，這得益於它們在創新、醫保報銷和臨床指南等方面對主要經濟領域的參與。這些國家透過監管決策、主導臨床試驗、進行醫療技術評估、建立移植中心網路以及引入包括CAR-T細胞療法和雙特異性抗體療法在內的先進療法，正在塑造全球標準。

來自多發性骨髓瘤治療市場主要國家的見解

美國是多發性骨髓瘤治療市場最具影響力的國家，這得益於其快速的FDA核准流程、積極的臨床試驗活動、強大的專科藥房網路、先進的移植和細胞治療基礎設施，以及對新型作用機制的早期應用。加拿大採用更集中化的准入模式，其報銷決策取決於臨床療效、成本效益、全國範圍的審查流程以及各省的實施情況。墨西哥和巴西是重要的拉丁美洲市場，需求不斷成長，但能否獲得治療取決於公共醫療保險覆蓋範圍、私人醫療保險覆蓋範圍、癌症治療中心的集中程度以及專科血液疾病服務的可及性。

為多發性骨髓瘤治療領域的領導企業提供實用建議。

產業領導企業應優先考慮差異化的臨床證據，這些證據需能證明在無惡化生存期、總存活期、微量殘存疾病陰性、安全性、便利性和病患報告結局方面具有顯著改善。隨著治療選擇日益飽和，產品需要展現其在特定患者群體中的價值，例如具有高危險細胞遺傳學特徵的患者、體弱老年患者、腎功能不全患者、既往接受過抗CD38治療的患者、三藥耐藥患者以及需要門診治療方案的患者。

多發性骨髓瘤治療藥物的分析調查方法

本執行摘要是基於符合醫藥市場情報最佳實踐的二手研究原則編寫而成。資訊來源包括公開的監管資料庫、臨床指南制定機構、同儕審查的癌症文獻、癌症流行病學資源、臨床試驗註冊庫、衛生技術評估（HTA）框架以及公開的政策文件。

結論：多發性骨髓瘤治療的未來前景

隨著免疫療法、標靶治療和精準治療策略的出現，多發性骨髓瘤治療市場正在迅速發展，並不斷改變治療標準。儘管對於許多患者而言，這種疾病仍然難以治愈，但透過聯合治療、維持療法、可測量的殘留病灶評估以及新型免疫療法，更深層的療效和更長的緩解期正變得越來越容易實現。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 多發性骨髓瘤治療市場：依藥物類別分類

  • 組蛋白去乙醯化酶抑制劑
  • 免疫調節劑
    • Lenalidomide
    • Pomalidomide
    • Thalidomide
  • 單株抗體
    • Daratumumab
    • Elotuzumab
    • 伊薩茨基馬
  • 蛋白酶體抑制劑
    • Bortezomib
    • Carfilzomib
    • 伊沙佐米

第8章 多發性骨髓瘤治療藥物市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第9章 多發性骨髓瘤治療市場：依治療方案分類

  • 聯合治療
    • 雙重聯合治療
    • 二次聯合治療
    • 三聯聯合治療
  • 單藥治療

第10章：多發性骨髓瘤治療藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第11章 多發性骨髓瘤治療市場：依患者年齡分類

  • 60歲或以上
  • 60歲以下

第12章 多發性骨髓瘤治療市場：依治療階段分類

  • 一線治療
  • 二線治療
  • 從第三行開始

第13章 多發性骨髓瘤治療市場：依病患類型分類

  • 新確診的患者
  • 復發患者
  • 難治性患者

第14章 多發性骨髓瘤治療市場：以最終用戶分類

  • 醫院
  • 專科診所
  • 癌症研究中心

第15章 多發性骨髓瘤治療藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 多發性骨髓瘤治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 多發性骨髓瘤治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc.
  • Adaptive Biotechnologies Corporation
  • Amgen Inc.
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellectis SA
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ichnos Glenmark Innovation
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Legend Biotech Corporation
  • Merck & Co., Inc.
  • MorphoSys AG
  • Novartis AG
  • Oncopeptides AB
  • Pfizer Inc.
  • PharmaMar, SA
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-036C5CF3A894

The Multiple Myeloma Drug Market is projected to grow by USD 13.46 billion at a CAGR of 7.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.22 billion
Estimated Year [2026] USD 8.80 billion
Forecast Year [2032] USD 13.46 billion
CAGR (%) 7.29%

Multiple Myeloma Drug Market Introduction

Multiple myeloma is a plasma cell malignancy and remains one of the most treatment-intensive segments of hematologic oncology. The disease is characterized by recurrent relapse, clonal evolution, bone marrow involvement, immunosuppression, renal complications, anemia, and bone disease, creating sustained demand for effective multiple myeloma drugs across newly diagnosed, relapsed, and refractory settings.

The market is being reshaped by proteasome inhibitors, immunomodulatory agents, corticosteroid combinations, anti-CD38 monoclonal antibodies, selective nuclear export inhibitors, BCMA-targeted therapies, CAR-T cell therapies, bispecific antibodies, and emerging cereblon E3 ligase modulators. Clinical practice continues to move toward earlier use of combination regimens, measurable residual disease assessment, and personalized sequencing based on patient fitness, cytogenetic risk, prior exposure, and treatment response.

According to widely used oncology references and public health sources such as WHO/IARC GLOBOCAN, the American Cancer Society, NCCN, ESMO, FDA, and EMA, multiple myeloma incidence rises sharply with age and remains a major cause of hematologic cancer mortality despite substantial therapeutic advances. This creates a durable need for innovation that improves depth of response, prolongs progression-free survival, reduces treatment burden, and expands access to advanced therapies.

Transformative Shifts in the Multiple Myeloma Drug Landscape

The multiple myeloma drug landscape is undergoing a structural shift from traditional chemotherapy-centered care to multi-mechanism, immune-based, and biomarker-informed treatment strategies. Anti-CD38 antibodies have become foundational in many frontline and relapse regimens, while BCMA-directed CAR-T therapies and bispecific antibodies are redefining expectations in heavily pretreated relapsed or refractory multiple myeloma.

A second transformative shift is the movement of high-efficacy therapies into earlier lines of treatment. Regulatory decisions and clinical trial results increasingly support the use of quadruplet regimens, maintenance optimization, and risk-adapted approaches that aim to deepen response and extend remission. At the same time, clinicians must manage cumulative toxicities such as cytopenias, infections, neuropathy, thromboembolic risk, and cytokine release syndrome.

Commercial strategy is also changing. Manufacturers are investing in subcutaneous formulations, outpatient administration models, companion diagnostics, real-world evidence generation, and payer-facing value dossiers. As more mechanisms enter the market, competitive differentiation depends on survival outcomes, safety, convenience, manufacturability, access programs, and evidence in high-risk populations.

Cumulative Impact of Artificial Intelligence on Multiple Myeloma Drugs

Artificial intelligence is becoming an enabling layer across multiple myeloma drug discovery, development, diagnosis, and treatment optimization. In research, AI-supported target discovery, protein modeling, screening prioritization, and translational analytics are helping identify novel antigens, resistance pathways, and rational combination strategies. These tools are particularly relevant in a disease marked by genomic heterogeneity and treatment-induced clonal evolution.

In clinical development, AI can improve trial design by supporting patient stratification, site selection, eligibility matching, synthetic control exploration, and real-time safety monitoring. For multiple myeloma, where endpoints such as progression-free survival, overall survival, minimal residual disease negativity, and quality of life are central, advanced analytics can strengthen evidence generation when used with validated datasets and transparent governance.

In care delivery, AI-enabled decision support may help interpret laboratory trends, imaging, cytogenetics, sequencing history, and adverse event risk. However, adoption depends on clinical validation, interoperability, bias mitigation, data privacy, and regulatory oversight. The strongest near-term impact is expected where AI augments clinician decision-making rather than replacing specialist judgment.

Key Regional Insights Across the Multiple Myeloma Drug Market

North America remains a leading region for multiple myeloma drug innovation due to high oncology spending, rapid uptake of FDA-approved therapies, extensive clinical trial infrastructure, and strong specialist networks. The United States anchors regional demand through broad adoption of anti-CD38 antibodies, CAR-T therapy, bispecific antibodies, and evidence-based guidelines, while Canada emphasizes health technology assessment and publicly funded access pathways. Across the region, treatment standards are strongly influenced by regulatory review, guideline updates, transplant eligibility assessment, specialty pharmacy distribution, and real-world safety monitoring.

Europe is defined by EMA approvals, national reimbursement negotiations, and guideline-driven adoption across major markets. The European Union supports harmonized regulatory oversight, but access timelines vary by country, particularly for high-cost cell and gene therapies. The United Kingdom, Germany, France, Italy, and Spain remain important markets due to specialized hematology centers, formal health technology assessment systems, and real-world evidence programs that evaluate clinical benefit, added therapeutic value, and budget impact.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, and India increase access to novel myeloma drugs, local clinical trials, and domestic biopharmaceutical development. China's regulatory modernization and growing oncology infrastructure are improving availability of innovative therapies, while Japan's aging population and advanced hematology practice support strong clinical demand. Latin America shows growing adoption in Brazil and Mexico but continues to face reimbursement, diagnostic capacity, and specialist access constraints. The Middle East, led by GCC health systems, is investing in oncology centers, medical tourism, and advanced therapeutics, while Africa remains underpenetrated due to limited specialist access, late diagnosis, constrained reimbursement, and uneven availability of advanced diagnostics.

Key Group Insights for Multiple Myeloma Drug Commercial Strategy

The G7 remains central to the multiple myeloma drug market because it includes major innovation, reimbursement, and clinical guideline economies such as the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom. These countries shape global standards through regulatory decisions, pivotal trials, health technology assessments, transplant center networks, and adoption of advanced therapies including CAR-T cells and bispecific antibodies.

The European Union provides a structured regulatory and pharmacovigilance environment through EMA oversight, while individual member states determine pricing and reimbursement. This creates a market where clinical value must be matched with cost-effectiveness evidence, real-world outcomes, budget impact management, and equitable access strategies. NATO countries collectively include advanced healthcare systems with strong demand for secure pharmaceutical supply chains, resilient medicine access, and coordinated preparedness for critical therapies, including oncology biologics and cell therapies.

BRICS economies are increasingly important due to large patient populations, expanding cancer infrastructure, and growing domestic pharmaceutical capabilities in China, India, Brazil, Russia, and South Africa. China and India are particularly relevant for clinical development, manufacturing capacity, biosimilars, and broader access initiatives, while Brazil and South Africa highlight the need for public-sector affordability strategies. ASEAN markets are improving oncology access through public-private investment, regional procurement strategies, and expanding specialist care, although availability of premium biologics remains uneven across member countries. GCC countries are prioritizing specialty care modernization, advanced hospital infrastructure, international clinical collaborations, and access to innovative oncology drugs for high-complexity hematologic malignancies.

Key Country Insights in the Multiple Myeloma Drug Market

The United States is the most influential country market for multiple myeloma drugs because of rapid FDA approvals, high clinical trial activity, strong specialty pharmacy networks, advanced transplant and cellular therapy capacity, and early adoption of novel mechanisms. Canada follows a more centralized access model, with reimbursement decisions shaped by clinical benefit, cost-effectiveness, pan-Canadian review processes, and provincial implementation. Mexico and Brazil are important Latin American markets where demand is rising, but access depends on public coverage, private insurance, oncology center concentration, and availability of specialized hematology services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent major demand centers with established hematology networks and formal health technology assessment processes. Germany often provides comparatively early post-approval access within Europe, while France, Italy, and Spain emphasize negotiated reimbursement, evidence of added therapeutic value, and managed access considerations. The United Kingdom combines guideline-driven care with cost-effectiveness assessment and specialized cancer networks. Russia maintains domestic oncology demand but faces access variability linked to procurement dynamics, local availability, and geopolitical constraints.

In Asia-Pacific, China is expanding through domestic innovation, regulatory reform, broader oncology insurance coverage, and rising clinical trial participation. Japan remains a high-value market with advanced clinical practice, strong safety monitoring, and an aging population that increases the clinical relevance of tolerable long-term regimens. India has a substantial patient base and strong generics and biosimilars capabilities, though affordability remains a barrier for premium therapies and advanced cell-based treatment. Australia and South Korea show high standards of oncology care, reimbursement scrutiny, active clinical research ecosystems, and strong interest in innovative immune-based treatments for relapsed or refractory multiple myeloma.

Actionable Recommendations for Multiple Myeloma Drug Leaders

Industry leaders should prioritize differentiated clinical evidence that demonstrates meaningful improvements in progression-free survival, overall survival, minimal residual disease negativity, safety, convenience, and patient-reported outcomes. As the treatment landscape becomes crowded, products must show value in defined patient groups such as high-risk cytogenetics, frail older adults, renal impairment, prior anti-CD38 exposure, triple-class refractory disease, and patients requiring outpatient-friendly treatment options.

Organizations should invest in access strategies early, including health economic models, real-world evidence, outcomes-based contracting, and patient support programs. For advanced therapies, manufacturing reliability, vein-to-vein time, outpatient administration readiness, referral pathway development, infection prevention, and toxicity management protocols are critical competitive factors.

Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional distributors can accelerate trial execution and market penetration. Leaders should also strengthen pharmacovigilance, equitable access planning, supply chain resilience, and lifecycle management through new formulations, rational combinations, label expansion, and earlier-line indications.

Research Methodology for the Multiple Myeloma Drug Analysis

This executive summary is built using secondary research principles aligned with pharmaceutical market intelligence best practices. Sources considered include public regulatory databases, clinical guideline organizations, peer-reviewed oncology literature, cancer epidemiology resources, clinical trial registries, health technology assessment frameworks, and publicly available policy documents.

The analysis emphasizes verified and widely recognized evidence from organizations such as the FDA, EMA, WHO/IARC, NCCN, ESMO, national cancer agencies, and published clinical trial data. Market interpretation focuses on therapy class evolution, regional access dynamics, patient segmentation, regulatory activity, clinical development trends, and adoption drivers rather than unsupported numerical forecasting.

Insights were synthesized through triangulation of epidemiology, treatment guidelines, regulatory approvals, clinical development trends, reimbursement considerations, safety requirements, and care delivery constraints. The methodology favors data-backed interpretation, transparent assumptions, and practical relevance for pharmaceutical manufacturers, investors, payers, providers, and commercial strategy teams.

Conclusion: Future Outlook for Multiple Myeloma Drugs

The multiple myeloma drug market is advancing rapidly as immunotherapy, targeted therapy, and precision treatment strategies reshape standards of care. While the disease remains largely incurable for many patients, deeper responses and longer remission periods are increasingly achievable through combination regimens, maintenance strategies, measurable residual disease assessment, and novel immune-directed therapies.

Future success will depend on clinical differentiation, earlier-line expansion, access to advanced therapies, real-world outcomes, manufacturing readiness, and the ability to serve diverse patient populations across mature and emerging markets. Organizations that combine scientific innovation with evidence-based access planning, AI-enabled development, supply chain resilience, and patient-centered delivery models will be best positioned to lead the next phase of multiple myeloma treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Multiple Myeloma Drug Market, by Drug Class

  • 7.1. Histone Deacetylase Inhibitors
  • 7.2. Immunomodulatory Agents
    • 7.2.1. Lenalidomide
    • 7.2.2. Pomalidomide
    • 7.2.3. Thalidomide
  • 7.3. Monoclonal Antibodies
    • 7.3.1. Daratumumab
    • 7.3.2. Elotuzumab
    • 7.3.3. Isatuximab
  • 7.4. Proteasome Inhibitors
    • 7.4.1. Bortezomib
    • 7.4.2. Carfilzomib
    • 7.4.3. Ixazomib

8. Multiple Myeloma Drug Market, by Line Of Therapy

  • 8.1. First Line
  • 8.2. Second Line
  • 8.3. Third And Beyond

9. Multiple Myeloma Drug Market, by Treatment Regimen

  • 9.1. Combination Therapy
    • 9.1.1. Doublet Regimen
    • 9.1.2. Quadruplet Regimen
    • 9.1.3. Triplet Regimen
  • 9.2. Monotherapy

10. Multiple Myeloma Drug Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Multiple Myeloma Drug Market, by Patient Age

  • 11.1. Sixty And Above
  • 11.2. Under Sixty

12. Multiple Myeloma Drug Market, by Line of Treatment

  • 12.1. First-Line Therapy
  • 12.2. Second-Line Therapy
  • 12.3. Third-Line and Beyond

13. Multiple Myeloma Drug Market, by Patient Type

  • 13.1. Newly Diagnosed Patients
  • 13.2. Relapsed Patients
  • 13.3. Refractory Patients

14. Multiple Myeloma Drug Market, by End-User

  • 14.1. Hospitals
  • 14.2. Specialty Clinics
  • 14.3. Cancer Research Centers

15. Multiple Myeloma Drug Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Multiple Myeloma Drug Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Multiple Myeloma Drug Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc.
  • 19.2. Adaptive Biotechnologies Corporation
  • 19.3. Amgen Inc.
  • 19.4. BeiGene, Ltd.
  • 19.5. Bristol-Myers Squibb Company
  • 19.6. Celgene Corporation
  • 19.7. Cellectis S.A.
  • 19.8. Daiichi Sankyo Company, Limited
  • 19.9. Gilead Sciences, Inc.
  • 19.10. GlaxoSmithKline plc
  • 19.11. Ichnos Glenmark Innovation
  • 19.12. Johnson & Johnson Services, Inc.
  • 19.13. Karyopharm Therapeutics Inc.
  • 19.14. Legend Biotech Corporation
  • 19.15. Merck & Co., Inc.
  • 19.16. MorphoSys AG
  • 19.17. Novartis AG
  • 19.18. Oncopeptides AB
  • 19.19. Pfizer Inc.
  • 19.20. PharmaMar, S.A.
  • 19.21. Regeneron Pharmaceuticals, Inc.
  • 19.22. Sanofi
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOMODULATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LENALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LENALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LENALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POMALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POMALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POMALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THALIDOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THALIDOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THALIDOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DARATUMUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DARATUMUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DARATUMUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ELOTUZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ELOTUZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ELOTUZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ISATUXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ISATUXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ISATUXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROTEASOME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BORTEZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BORTEZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BORTEZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARFILZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARFILZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARFILZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IXAZOMIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IXAZOMIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IXAZOMIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THIRD AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THIRD AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THIRD AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DOUBLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL QUADRUPLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRIPLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SIXTY AND ABOVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL UNDER SIXTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL UNDER SIXTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL UNDER SIXTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEWLY DIAGNOSED PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RELAPSED PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL REFRACTORY PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 215. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 247. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 258. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 267. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 271. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 323. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 324. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 345. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 346. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 347. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 348. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 349. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 350. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 352. FRAN